Find out which microRNAs and long noncoding RNAs are drawing the most attention in research right now.!--h2>
Enal Razvi, Ph.D.
Gary Oosta, Ph.D.
The focus of this report is to frame and document our methodology for en bloc analysis of the academic publications documenting associations of specific molecular entities with specific biological phenotypes. These associations can then be empirically tested using defined clinical samples and associated clinical histories, if available.
This approach is particularly suitable to studying biomarkers since the publications universe in this domain is extensive and fragmented; this offers the opportunity for the en bloc analysis to reveal specific associations/trends that may be amenable to be tested. Another value proposition of this analysis is to prioritize molecular markers for biomarker potential based on the depth of penetrance in the scientific literature and the types of studies performed that suggest such potential.
Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at firstname.lastname@example.org.
Gary M. Oosta holds a Ph.D. in Biophysics from Massachusetts Institute of Technology and a B.A. in Chemistry from E. Mich. Univ. He has 25 years of industrial research experience in various technology areas including medical diagnostics, thin-layer coating, bio-effects of electromagnetic radiation, and blood coagulation. Dr. Oosta has authored 20 technical publications and is an inventor on 77 patents worldwide. In addition, he has managed research groups that were responsible for many other patented innovations. Dr. Oosta has a long-standing interest in using patents and publications as strategic technology indicators for future technology selection and new product development.